Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227901 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02227901: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02227901 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02227901, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of tipifarnib when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme. Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tipifarnib together with radiation therapy and temozolomide may be a better way to treat glioblastoma multiforme.
Interventions
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- DRUG Temozolomide
- DRUG Tipifarnib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2002-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02227901
The ClinicalTrials.gov registry entry for NCT02227901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which External Beam Radiation Therapy is the first listed.
NCT02227901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02227901 about?
NCT02227901 is a clinical study titled "Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". This phase I trial studies the side effects and best dose of tipifarnib when given together with radiation therapy and temozolomide in treating patients with newly diagnosed glioblastoma multiforme. Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....
What is the current status of trial NCT02227901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2002-09. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02227901?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Temozolomide (DRUG), Tipifarnib (DRUG).
Who is sponsoring clinical trial NCT02227901?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.